Navigation Links
Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
Date:1/30/2008

- 4Q EPS Grows 21.8% to $0.72 on 19.8% Revenue Growth -

PRINCETON, N.J., Jan. 30 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today reported earnings for its fourth quarter ended December 31, 2007 of $0.78 per diluted share and full-year EPS of $2.71; both periods include a $0.06 per share gain from the sale of its centralized ECG business. Excluding the gain on sale, earnings were $0.72 per diluted share in the fourth quarter, representing 21.8% year-over-year EPS growth, and $2.65 per diluted share for the full-year, representing annual EPS growth of 20.5% over 2006 EPS of $2.20 (which excludes a $0.04 per share tax gain from the 2006 results).

"I congratulate the entire Covance team for another year of outstanding achievement for our clients and shareholders. Increasing levels of client satisfaction led to strong repeat work resulting in more than $500 million in net orders for the quarter and a 20.6% growth in our backlog to $2.7 billion," said Joe Herring, Chairman and Chief Executive Officer. "In the fourth quarter, revenue growth was robust at 19.8% and operating margins remained solid at 14.8%. Performance reflected strong demand for both our early- and late-stage development service offerings. In addition, we significantly reduced our DSO to 36 days, the lowest level in more than 5 years, helping to drive strong free cash flow for the quarter and the year.

"In 2007, our capital expenditures exceeded $200 million, with a substantial portion allocated to investments in capacity expansion and IT infrastructure to support our future growth. Covance's consistent history of generating strong returns on capital combined with the increasing demand for our drug development services, leads us to increase strategic capital investment in 2008 in order to support our long-term growth opportunity.

"Our ongoing success with productivity enhancements made a significant contribution again in 2007, as evidenced by a 4.3% increas
'/>"/>

SOURCE Covance Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Covance Inc. Invites You to Join the Webcast of Its Third Quarter 2007 Financial Results Conference Call
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... , ... VetStem Biopharma will be offering weekly private guided tours of our ... , The tour and course will be given every Wednesday at 6pm to local ... Staff members are welcome to attend with their veterinarian as well. Participants will be ...
(Date:7/28/2015)... YORK , July 28, 2015 Tauriga ... a diversified life sciences company, today announced that its ... shares of common stock of the Company from 1,000,000,000 ... on July 27, 2015 at the Law Offices of ...  At the Special Meeting, there were 480,655,929 shares of ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix Inc. ... 1 clinical trial with MMI-0100, a first-in-class inhibitor ... developed for pulmonary disorders characterized by inflammation and ... United Kingdom , is a double-blind, two-way ... the safety and tolerability of MMI-0100 when given ...
(Date:7/28/2015)... 28, 2015 CSL Behring announced ... accepted for review the company,s Biologics License Application (BLA) ... for the treatment of hemophilia A. In the pivotal ... Hemophilia A is a congenital bleeding ... all affected patients are male. People with hemophilia A ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3
... CVM ) reports financial results for the three and nine ... for the quarter ended June 30, 2008,was $2,176,679 versus a ... loss from operations for the nine months ended June 30, ... nine months in,2007., The net loss per common share ...
... MedPredict, a global,provider of pharmaceutical competitive intelligence ... critical strategic insight for pharma,and biotech companies with ... therapies., Biogen/Elan,s Tysabri has been under scrutiny ... rare and potentially fatal brain disease,associated with use ...
... Strategic Fit with Lilly,s Animal Health Division, GREENFIELD, ... and Company (NYSE: LLY ), today announced that ... to the dairy cow supplement,Posilac(R) (sometribove), as well as ... )., "Global dairy demand is increasing, outstripping supply, ...
Cached Biology Technology:CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 2CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 3CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 4CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 5Expert Neurology Panel Weighs Impact of New Reports of PML in Multiple Sclerosis Patients on Tysabri 2Elanco Announces Acquisition of Posilac(R) Dairy Business 2Elanco Announces Acquisition of Posilac(R) Dairy Business 3
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new ... fully hardware encapsulated fingerprint sensor and matching ... is literally off the grid, isolating fingerprint ... within the fingerprint sensor to provide ultimate ...
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
(Date:7/8/2015)... CORAL SPRINGS, Florida , July 8, 2015 ... is constantly evolving as this summer,s must have products such ... high in demand as popularity for biometrics based devices continues ... today are NXT-ID, Inc. (NASDAQ: NXTD ), Google Inc. ... Fitbit Inc. (NYSE: FIT ), GoPro, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6
... Neck, NY June 3, 2008) -- New ... leading charity dedicated to mental health research, and ... into how genes work to impair various aspects ... associated with many psychiatric illnesses, such as schizophrenia, ...
... humble earthworm, famously acknowledged by Charles Darwin when he ... other animals which have played so important a ... new sensitive and detailed picture of what is going ... in two BioMed Central journals shows that copper contamination ...
... human malaria parasite, Plasmodium falciparum, which is responsible for ... becoming sexually mature. The discovery could ... which is a major public health problem and which ... of Plasmodium falciparum is complex, and it is not ...
Cached Biology News:At Boston symposium, NARSAD researchers report on genes and family traits 2At Boston symposium, NARSAD researchers report on genes and family traits 3At Boston symposium, NARSAD researchers report on genes and family traits 4At Boston symposium, NARSAD researchers report on genes and family traits 5At Boston symposium, NARSAD researchers report on genes and family traits 6Earthworm detectives provide genetic clues for dealing with soil pollution 2
Adult Bovine Serum US Origin...
... 13(S)-HODE-d4 contains 4 deuterium atoms at the ... intended for use as an internal standard for ... spectrometry. 13(S)-HODE is produced by incubation of linoleic ... been shown to inhibit the adhesion of tumor ...
...
...
Biology Products: